DrugPatentWatch Database Preview

Details for Patent: 6,888,027

« Back to Dashboard

Which drugs does patent 6,888,027 protect, and when does it expire?

Patent 6,888,027 protects BELEODAQ and is included in one NDA.

This patent has sixteen patent family members in eleven countries.

Summary for Patent: 6,888,027

Title:	Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
Abstract:	This invention pertains to certain active carbamic acid compounds which inhibit HDAC activity and which have the following formula: (I) A is an aryl group; Q.sup.1 is a covalent bond or an aryl leader group; J is a sulfonamide linkage selected from: --S(.dbd.O).sub.2 NR.sup.1 -- and --NR.sup.1 S(.dbd.O).sub.2 --; R1 is a sulfonamido substituent; and, Q.sup.2 is an acid leader group; with the proviso that if J is --S(.dbd.O).sub.2 NR.sup.1 --, then Q.sup.1 is an aryl leader group; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and, e.g., to inhibit proliferative conditions, such as cancer and psoriasis. ##STR1##
Inventor(s):	Watkins; Clare J (Abingdon, GB), Romero-Martin; Maria Rosario (Didcot, GB), Moore; Kathryn G (Abingdon, GB), Ritchie; James (Abingdon, GB), Finn; Paul W (Abingdon, GB), Kalvinsh; Ivars (Riga, LV), Loza; Einars (Riga, LV), Dikovska; Klara (Riga, LV), Gailite; Vija (Riga, LV), Vorona; Maxim (Riga, LV), Piskunova; Irina (Riga, LV), Starchenkov; Igor (Riga, LV), Andrianov; Victor (Riga, LV), Harris; C. John (Sittingbourne, GB), Duffy; James E. S. (Sittingbourne, GB)
Assignee:	Topotarget UK Limited (Abingdon, GB)
Application Number:	10/381,790
Patent Claim Types: see list of patent claims	Compound; Composition; Use;

Drugs Protected by US Patent 6,888,027

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Spectrum Pharms	BELEODAQ	belinostat	POWDER;IV (INFUSION)	206256-001	Jul 3, 2014		RX	Yes	Yes			Y	Y		TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA (PTCL).

Foreign Priority and PCT Information for Patent: 6,888,027

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	0023986	Sep 29, 2000

PCT Information
PCT Filed	September 27, 2001	PCT Application Number:	PCT/GB01/04326
PCT Publication Date:	April 18, 2002	PCT Publication Number:	WO02/30879

Non-Orange Book US Patents Family Members for Patent 6,888,027

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
7,183,298	Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
7,557,140	Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
7,407,988	Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors

International Family Members for US Patent 6,888,027

Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2001290131
Australia	9013101
Canada	2423744
Canada	2765409